F. Ricciardolo (Orbassano (To), Italy), P. Sterk (Amsterdam, Netherlands)
Effect of the addition of montelukast on airway inflammation and remodeling in symptomatic asthma
M. Hoshino (Atami, Japan)
|   |
Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients
T. Southworth (Manchester, United Kingdom)
| |
Living with severe asthma year 2016
P. Katsaounou (Athens, Greece)
| |
Effect of tralokinumab on GINA control in severe, uncontrolled asthma
C. Brightling (Leicester, United Kingdom)
| |
The therapeutic efficacy of OAT-889 (dual AMCase/CHIT1 inhibitor) in comparison to montelukast in HDM-induced model of chronic airway inflammation in mice
B. Dymek (Warszawa, Poland)
| |
PDK1/RSK1-dependent C/EBPß activation is involved in thrombin-induced expression of orosomucoid 1-like 3 (ORMDL3) and IL-8/CXCL8 in human lung epithelial cells
B. Chen (Taipei, Taiwan)
| |
Long term effect of doxycycline in asthma: a real world observation
P. Bhattacharyya (Kolkata (West Bengal), India)
| |
Clinically meaningful improvements with reslizumab in patient-reported outcomes and lung function in a sub-population defined by the EU indication with =3 exacerbations
L. Bjermer (Lund, Sweden)
| |
Genome-wide association study of inhaled corticosteroid response in African-admixed children with asthma.
N. Hernandez-Pacheco (Santa Cruz de Tenerife, Spain)
| |
Perceived and actual control in patients with severe asthma: results from a global online survey
P. Katsaounou (Athens, Greece)
| |
Clinically meaningful FEV1 response with reslizumab achieved early and sustained over 52 weeks
J. Virchow (Rostock, Germany)
| |
Reslizumab reduces severe exacerbations associated with emergency department visit or hospitalization and improves measures of lung function in patients on maintenance oral corticosteroids (OCS) at baseline
P. Chanez (Marseille, France)
| |
Impact of A Digital Health Intervention On Asthma Healthcare Utilization
R. Merchant (San Francisco, United States of America)
| |
Fevipiprant (QAW039) demonstrates safety, tolerability and consistent PK at high oral doses
V. Erpenbeck (Basel, Switzerland)
| |
Maternal eCigarette vaping enhances Th2 driven asthma in the offspring.
P. Sharma (Glebe, Australia)
| |
Curcumin as an Add-on Therapy of Moderate Partially Controlled Asthma
E. Jusufovic (Tuzla, Bosnia and Herzegovina)
| |
Response to omalizumab treatment according to blood eosinophil count: Results of a French real-world study (STELLAIR)
M. Humbert (Paris, France)
| |
Relationship between benralizumab exposure and asthma exacerbation rate for patients with severe asthma
L. Roskos (Gaithersburg, United States of America)
| |